Introduction: Most pulmonary nodules found on imaging studies are indeterminate, but because of the concern for lung cancer, all patients require further evaluation with resultant radiation risk, significant cost, and delays in diagnosis. We hypothesized that a diagnostic blood test based on detection of autoantibodies against cancer antigens would be able to distinguish a benign nodule from lung cancer.
Introduction
The National Lung Screening Trial reported a 20% relative reduction in lung cancer mortality with low-dose computed tomography; however, almost 40% of participants had an indeterminate radiographic abnormality. 1 Most of the lesions were benign, but because of the concern for lung cancer, further evaluation with resultant radiation risk, significant cost, and delays in diagnosis was required. Therefore, we aimed to develop a serum autoantibody panel to complement imaging and distinguish benign from malignant lesions.
Methods
This study was approved by the Duke Health System's institutional review board, and all patients signed informed consent. Using several different strategies, we identified a panel of 25 serum autoantibodies associated with NSCLC. In the first discovery method, we used serum samples from patients with NSCLC and age-, sex-, and smoking history-matched controls to probe Western blots of proteins obtained from whole cell lysates of human NSCLC cell lines, conditioned media from these cell lines, and immunoglobulin G-depleted sera from patients with NSCLC. We then looked for differentially *Corresponding author.
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represented immunoreactive bands on the Western blots. In the second discovery method, we used immunoglobulin G purified from the pooled sera of NSCLC patients to immunoprecipitate putative tumor antigens from pooled NSCLC cell lysates. We proceeded to identify the autoantigens discovered by both methods as summarized in the following paragraphs. Details of this procedure have been described previously. 2 For autoantigen identification, we probed twodimensional polyacrylamide gel electrophoresis blots of the appropriate antigen source with each immunoreactive serum. We then used the location of the immunoreactive spot as a guide to locate the protein of interest on a duplicate Coomassie-stained two-dimensional polyacrylamide gel electrophoresis gel of the same sample. Proteins in the stained spot were identified at the Duke Proteomics Facility by in-gel tryptic digestion, matrix-assisted laser desorption/ionization timeof-flight (mass spectrometry) peptide fingerprinting, and nanoscale liquid chromatography coupled to tandem mass spectrometry.
We supplemented these antigen discovery platforms with four tumor antigens reported in the literature.
3-5 A microarray containing the 25 antigens (Table 1) was constructed and probed with sera from 125 patients with NSCLC and 125 age-, sex-, and smoking historymatched controls with a benign nodule. Stage, nodule size, and histologic data for the patients with NSCLC are summarized in Table 2 . The data set was randomly divided into training and validation data sets with equal numbers of patients with and without cancer. Logistic regression analysis was performed and C-statistics were computed.
Results
In the training data set the logistic regression c-index statistic was 0.691. In the validation data set, the model predicting the score generated from the training set model had a c-index of 0.490. The relationship between the score and outcome (final diagnosis) was not statistically significant (p ¼ 0.460). No correlation of autoantibody level with stage, nodule size, or histologic type was noted.
Discussion
Numerous studies have attempted to develop serum autoantibody panels to diagnose different types of cancer, but none of have truly affected clinical management. The panels that have been developed to date do not have sufficient accuracy, and meta-analyses of autoantibody panels have found them to be lacking in sensitivity and specificity. 6, 7 Recently, the EarlyCDT-Lung blood test (Oncimmune Ltd., Nottingham, United Kingdom) has been proposed to assess the risk for lung cancer. 8 This test is based on detection of seven autoantibodies. In various models, increased specificity was achieved at the cost of sensitivity. For indeterminate pulmonary nodules in the 4-to 20-mm size range, a positive test result predicted a 2.7-fold increased relative risk for the development of lung cancer. The full utility of this test in clinical practice remains to be determined.
The current study combined tumor antigens discovered by using new approaches (many of these antigens have prior associations to cancer) with well-established tumor antigens (annexin, p53, and PGP9.5), but again the accuracy was insufficient for clinical practice. We should be cautious in drawing conclusions from a single study with a sample size of only 250. In addition, technical considerations, including antigen selection and assay format, may be partially responsible for the suboptimal results. However, there also appear to be real inherent biological limitations of autoantibodies as cancer biomarkers. First, although much is known about the generation of antibodies in infectious and autoimmune diseases, the development and function of antibodies against tumors remains to be fully characterized. In a recent study exploring tumor-infiltrating lymphocytes, all of the isolated single B cells produced monoclonal antibodies that were polyreactive.
2 Thus, although a patient's serum may appear positive for a given autoantigen, the signal could be due to antibodies that also react to proteins unrelated to the tumor. If possible, it may be necessary to design the test such that polyreactivity of antibodies is minimized.
Second, recent studies have shown that somatic mutations found in cancers can also be detected in normal tissue. 9 These neoantigens could potentially produce an autoantibody response in the absence of cancer. Both of these features, among others, reduce the inherent ability of a panel to establish a specific-cancer diagnosis. Finally, tumors are heterogeneous, which ultimately limits the sensitivity of autoantibody assays. As more is understood about the complex immune response to the heterogeneous composition of tumors, it may be possible to find solutions to fundamental issues that currently limit the accuracy of serum autoantibodies for cancer detection.
